A VALIDATED REVERSE-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-CHARGED AEROSOL DETECTOR TECHNIQUE FOR THE SIMULTANEOUS ESTIMATION OF SITAGLIPTIN AND ERTUGRILFOZIN IN PURE AND PHARMACEUTICAL DOSAGE FORMS

ANJANEYULU REDDY B1*, RADHAKRISHNANAND P2, IRSHAD ALAM MD1, RAVI KIRAN P4

1Department of Faculty of Science, Pacific Academy of Higher Education and Research University, Udaipur, Rajasthan, India. 2Department of Daicel Chiral Technologies, Hyderabad, Telangana, India. 3Department of Faculty of Science and Technology, Babasaheb Ambedkar Marathwada University, Aurangabad, Maharashtra, India. 4Department of Chemistry, BITS-Pilani, Medchal, Telangana, India. Email: anjireddyss98@gmail.com

Received: 02 February 2019, Revised and Accepted: 09 April 2019

ABSTRACT

Objective: The main objective of the present work is to develop and validate a selective reverse-phase (RP) high-performance liquid (HPLC)-charged aerosol detection technique for the quantitation of the sitagliptin and ertugliflozin in dosage form to attain high degree of sensitivity.

Materials and Methods: In present HPLC technique, separation of drugs was achieved on Phenomenex C18 column (250×4.6 mm, 5 µ) with a mobile phase composition of phosphate buffer (pH 3.5), acetonitrile, and methanol in the proportion of 40:40:20%V/V. 1 ml/min flow rate and 256 nm wavelength detection were maintained for the elution of drugs in the chromatographic system. The retaining time of sitagliptin and ertugliflozin in column was found to be 4.2 and 2.4 min, respectively.

Results: The projected technique was successfully applied for the quantitation of sitagliptin and ertugliflozin as a single combined mixture. The linearity statistics for calibration curves shown a good linearity in the concentration range of 0.3125–10 µg/ml for sitagliptin and 0.0625–2.5 µg/ml for ertugliflozin. The average values of regression coefficient, slope, and intercept were 0.9998, 8688.2, and 1977.6 for sitagliptin and 0.9996, 33602, and 1852.6 for ertugliflozin. The technique was validated as per the International Council for Harmonization guidelines. The limit of detection and limit of quantification findings were 0.002 and 0.247 µg/ml for sitagliptin and 0.04 and 0.12 µg/ml for ertugliflozin.

Conclusion: The developed and validated RP-HPLC-charged aerosol detector technique of sitagliptin and ertugliflozin in dosage form showed that the method was accurate and selective with high degree of sensitivity.

Keywords: Ertugliflozin, Sitagliptin, Diabetes mellitus, Reverse-phase high-performance liquid chromatography-charged aerosol detector, Linearity and validation.

INTRODUCTION

The charged aerosol detector (CAD) is a universal detection system used to quantify the amount of chemical compounds present in a sample by the process of creating charged aerosol particles which were detected by an electrometer. Reverse-phase (RP) high-performance liquid chromatography (HPLC) with CAD detection system was used in this work to quantify the drugs with high degree of sensitivity. Sitagliptin chemically designated as (R)-4-oxo-4-(3-[trifluoromethyl]-5,6-dihydro[2H]pyrazin-7(8H)-y1)-1-(2,4,5-trifluorophenyl)butan-2-amine with molecular formula C18H14F3N4O (Fig. 1) and molecular mass of 407.314 g/mol. It was used as an adjunct along with exercise and diet to progress glycemic control in type-II diabetes mellitus patients [1-3]. Sitagliptin obstructs the dipeptidyl peptidase (DPP-4) enzyme competitively. This DPP-4 enzyme breaks down the glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP) incretins, hormones released in gastrointestinal in response to meal by inhibiting the activation of GLP-1 and GIP, increases the insulin secretion and decrease the glucagon release by the α-cells of pancreas. This process leads to normal blood glucose levels in the body. When blood glucose approaches normal level, the insulin amount released, and suppression of glucagon diminishes, this nurture is to inhibit an “overshoot” and consequent low blood sugar levels as seen with some kind of oral hypoglycemic drugs [4,5]. Ertugliflozin chemically designated as [1S,2S,3S,4R,5S]-5-J-Chloro-3-(4-ethoxybenzyl) phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol with molecular formula C24H22ClNO8 (Fig. 2) and molecular weight of 436.69 g/mol [7-9]. The glucose reabsorption process is mediated by sodium-glucose cotransporters (SGLT) mainly in the Type-II diabetes which is accountable for 90% of the reabsorbed glucose. It inhibits SGLT-2 and its activity raises the glucose elimination, decreases hyperglycemia without any requirement of insulin secretion. It progresses the control of glycemia in Type-II diabetes patients [10].

In this paper, we demonstrated the development of RP-HPLC technique using Corona CAD for the quantification of sitagliptin and ertugliflozin. CAD is a universal and highly sensitive detector (Fig. 3), which provides a consistent response for all analytes and has a suitable dynamic range for quantification of sitagliptin and ertugliflozin [11-14]. According to literature, there are no reports of RP-HPLC-CAD technique for the simultaneous quantitation of sitagliptin and ertugliflozin as of now with high sensitivity [15-22]. Few analytical techniques were available with less sensitivity [19,20,22] for the quantification of these drugs by HPLC with ultraviolet and photodiode array. Thus, there is a need for the development of highly sensitive method for the estimation of both drugs using CAD.

MATERIALS AND METHODS

Reagents and chemicals

All the HPLC-grade solvents procured from Sigma-Aldrich (St. Louis Missouri, USA), HPLC-grade water obtained from Milli-Q system (Millipore, Billerica, MA). The reference standards of ertugliflozin and sitagliptin were obtained from Aldrich, St. Louis Missouri, USA, and Billerica, MA, USA, respectively. The HPLC-grade solvents procured from Sigma-Aldrich (St. Louis Missouri, USA), and Milli-Q water obtained from Millipore, Billerica, MA, USA, were used in the HPLC system. The reference standards of ertugliflozin and sitagliptin were obtained from Aldrich, St. Louis Missouri, USA, and Billerica, MA, USA, respectively.
gift samples supplied by MSN Laboratories, Hyderabad, India. Ertugliflozin and sitagliptin (15 mg/100 mg) marketed product (Steglujan tablets) bought from local pharmacy. All other chemicals of analytical grade were bought from Qualigens Fine Chemicals, Mumbai, India.

**Chromatographic system and equipment**

Waters-2590 series LC system with Thermo (ESA-corona) CAD detector. The equipments utilized in the work were Sigma-200 electronic balance, PCI-3.5 L sonicator, Universal hot air oven, and Unilab Digital pH Meter.

**Preparation of phosphate buffer pH – 5.8**

Transfer the mixture containing 8.5 ml of 1 M K2HPO4 and 91.5 ml of 1 M KH2PO4 into a 1000 ml volumetric flask and make up the volume to mark with HPLC-grade water and sonicate the resulting solution for 10 min.

**Preparation of mobile phase**

Preparation of mobile phase done by mixing methanol, acetonitrile, and phosphate buffer (pH – 5.8) in the proportion of 20:40:40% V/V. The resultant mobile phase was degasified by sonication and vacuum filtration 0.45-micron nylon filter.

**Preparation of standard stock solutions**

Standard stock methanolic solutions of the drugs were prepared in concentrations of 1 mg/ml of each of sitagliptin and ertugliflozin [22-25]. Solutions were processed by transferring 100 mg of sitagliptin and ertugliflozin into separate 100 ml volumetric flasks containing 40 ml of methanol, sonication for 5 min. The final volume was made by methanol. The processed stocks were kept at 2–8°C.

**Preparation of sample solution**

Ten tablets of each of studied drug were accurately weighed, transferred to a clean, dry mortar, and ground to fine powder. A powder equivalent to 100 mg sitagliptin and 15 mg ertugliflozin was transferred into a separate 100 ml volumetric flask, 40 ml methanol was added, sonication for 10 min and diluted to the volume with methanol. The resultant solution filtered through 0.45 μm pore size nylon filter membrane.

**Chromatographic conditions**

Drugs were resolved in the liquid chromatographic system consisting Phenomenex C18 column (250×4.6 mm, 5 μ) with a mobile phase mixture of methanol, acetonitrile, and phosphate buffer (pH 5.8) in the proportion of 20:40:40% V/V. Flow rate of 1 ml/min and
Corona charged aerosol detection was used for the elution of drugs in the chromatographic system. The retention time of sitagliptin and ertugliflozin was found to be at 4.2 and 2.4 min, respectively.

RESULTS AND DISCUSSION

Optimization of RP-HPLC-CAD method
Both drugs were exposed to chromatographic conditions using different mobile phases of different pH values, different columns, and flow rates. The variation in retention times, selectivity and sensitivity of drugs were observed with changes in the mobile phase, columns, flow rate, and pH. Initially, acetonitrile:water in different proportions was used, but poor separation of peaks was detected; then, methanol:water and methanol:buffer in different proportions and different pH values were tried, but low sensitivity and splitting of peaks were observed. Later, methanol, acetonitrile, and buffer at different pH were tried. Best results were given on methanol, acetonitrile, and phosphate buffer (pH 5.8) in the proportion of 20:40:40% V/V with 1 ml/min flow rate on Phenomenex C18 column (250×4.6 mm, 5 µ).

Validation
Optimized RP-HPLC-CAD technique was validated as per the International Council for Harmonization validation parameters [26-30].

Precision
The method precision was confirmed by system precision and intermediate precision. System precision carried out to determine the HPLC system condition. System precision was calculated by infusing six standard solutions, and finally, the percentage relative standard deviation (RSD) was calculated from the peak response [28]. Intermediate precision was evaluated by the examination of three dissimilar concentrations on different days and percentage RSD values were determined by calculating from resultant findings. Results for precision are shown in Tables 1 and 2.

Accuracy
Developed method accuracy was processed by studying recovery at three dissimilar concentrations of sitagliptin and ertugliflozin by triplicate analysis (n=3) [23]. The results found from the determination of accuracy were expressed in the form of percentage recovery and finding is shown in Table 3.

Limit of detection (LOD) and limit of quantification (LOQ)
These were determined separately on the basis of standard calibration curve (Figs. 5 and 6). The residual standard deviation of the regression line or the standard deviation of y-intercepts of regression lines was utilized to calculate LOD and LOQ [22]. Sensitivity of the proposed technique was determined in terms of LOD and LOQ using the following formulae.

\[
\text{LOD} = 3.3 \times \frac{\sigma}{S}
\]
\[
\text{LOQ} = 10 \times \frac{\sigma}{S}
\]

Where, \(\sigma\) = Standard deviation determined from the calibration curve.
\(S\) = Slope from calibration curve.

The findings are tabulated in Table 1.

### Table 1: Sitagliptin and ertugliflozin system suitability parameters

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Ertugliflozin</th>
<th>Sitagliptin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linearity</td>
<td>0.0625–2.5 µg/ml</td>
<td>0.3125–10 µg/ml</td>
</tr>
<tr>
<td>Retention time</td>
<td>2.4 min</td>
<td>4.2 min</td>
</tr>
<tr>
<td>Resolution</td>
<td>-</td>
<td>More than 2</td>
</tr>
<tr>
<td>LOD</td>
<td>0.040</td>
<td>0.082</td>
</tr>
<tr>
<td>LOQ</td>
<td>0.120 µg/ml</td>
<td>0.247 µg/ml</td>
</tr>
</tbody>
</table>

LOD: Limit of detection, LOQ: Limit of quantification

### Table 2: Precision study of sitagliptin and ertugliflozin

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Concentration (µg/ml)</th>
<th>Repeatability (n=6) % RSD</th>
<th>Intermediate precision (n=6) % RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitagliptin</td>
<td>3</td>
<td>0.294</td>
<td>1.740</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>0.242</td>
<td>1.145</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>1.010</td>
<td>1.014</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>0.45</td>
<td>1.414</td>
<td>1.641</td>
</tr>
<tr>
<td></td>
<td>0.9</td>
<td>0.566</td>
<td>1.232</td>
</tr>
<tr>
<td></td>
<td>1.35</td>
<td>0.426</td>
<td>1.002</td>
</tr>
</tbody>
</table>

n=6: Number of replicates; RSD=RSD, RSD: Relative standard deviation

### Table 3: Accuracy of sitagliptin and ertugliflozin

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Concentration (µg/ml)</th>
<th>% recovery statistical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ertugliflozin</td>
<td>0.45 µg/ml</td>
<td>Mean±SD</td>
</tr>
<tr>
<td>98.0±101.00</td>
<td>Mean±SD</td>
<td>99.3±1.247</td>
</tr>
<tr>
<td>99.00</td>
<td>% RSD</td>
<td>1.255</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>0.9 µg/ml</td>
<td>Mean±SD</td>
</tr>
<tr>
<td>96.0±99.00</td>
<td>Mean±SD</td>
<td>97.8±1.239</td>
</tr>
<tr>
<td>99.00</td>
<td>% RSD</td>
<td>1.247</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>1.35 µg/ml</td>
<td>Mean±SD</td>
</tr>
<tr>
<td>97.0±97.00</td>
<td>Mean±SD</td>
<td>97.3±1.247</td>
</tr>
<tr>
<td>99.00</td>
<td>% RSD</td>
<td>1.281</td>
</tr>
</tbody>
</table>

RSD: Relative standard deviation, SD: Standard deviation
Specificity
Method specificity was evaluated from the chromatograms (Figs. 7-10) where complete separation of sitagliptin and ertugliflozin was attained [17]. The peak responses found were well separated with good baseline as shown in Fig. 7-10 and the resolution for all peaks was more than 2 as documented in Table 1.

Robustness
The robustness of the proposed HPLC method was assessed by the ability to remain unaffected by small changes in experimental conditions [24,30]. Change in flow rate by ±0.1 ml and small changes in mobile phase organic strength by ±1 ml have no significant effect on chromatographic resolution. Results are presented in Table 4.

Application of the method
Steglujan marketed tablets were estimated by infusing sample solution into LC system under optimized chromatographic conditions. Steglujan each tablet contains 15 mg of ertugliflozin and 100 mg of sitagliptin. The amount of drugs present in the formulation was determined from the calibration curve method. The results of the assay method are shown in Table 5.

Table 4: Robustness of ertugliflozin and sitagliptin

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Variation</th>
<th>% RSD</th>
<th>Ertugliflozin</th>
<th>Sitagliptin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robustness</td>
<td>Change in flow rate</td>
<td>0.92</td>
<td>0.45</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(+0.1 ml/min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Change in mobile</td>
<td>0.56</td>
<td>0.86</td>
<td></td>
</tr>
<tr>
<td></td>
<td>phase (+1 ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RSD: Relative standard deviation
Table 5: Application of developed RP-HPLC-CAD method to tablet formulation

<table>
<thead>
<tr>
<th>Dosage form of drug</th>
<th>Labeled amount in mg/tab</th>
<th>Recovered amount in mg Mean±2SD</th>
<th>% CV</th>
<th>% assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stagliujan tablet(s)</td>
<td>15</td>
<td>14.96±0.620</td>
<td>0.62</td>
<td>99.79</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>100</td>
<td>99.75±0.154</td>
<td>0.63</td>
<td>99.75</td>
</tr>
</tbody>
</table>


CONCLUSION
A simple and sensitive RP-HPLC-CAD technique was developed successfully for the simultaneous analysis of sitagliptin and ertugliflozin with good resolution value between the drugs. The CAD detection system was used in this work to give high degree of sensitivity to analytical method for the detection of sitagliptin and ertugliflozin when compared with the existing methods. Sitagliptin and ertugliflozin were linear in the concentration range of 0.3125–10 μg/ml and 0.0625–2.5 μg/ml, respectively. The average values of the correlation coefficient, slope, and intercept were 0.9998, 8680.2, and 1977.6 for sitagliptin and 0.9996, 33602, and 1852.6 for ertugliflozin. The analytical method shows high degree of precision and accuracy with not more than 2% of RSD values. The present analytical method was simple, rapid, accurate, and precise and can easily applicable for routine quantification of the two drugs in bulk and formulations such as capsules, tablets, and powders.

AUTHORS’ CONTRIBUTIONS
All authors contribute equally to this manuscript.

CONFLICTS OF INTEREST
The authors declare that there are no conflicts of interest regarding the publication of this paper.

REFERENCES